TABLE 3.
Summary of EV targeting strategies used in regenerative medicine.
Targeting moieties | Target | Method of conjunction | Cargo | Loading method | Administration | EV/exosome origin | Application areas | Ref |
---|---|---|---|---|---|---|---|---|
RGD | αvβ3 overexpressing cells (HUVEC) | DSPE-PEG-RGD | Ac4ManNAz | Reversible permeabilization, click chemistry | In vitro/in vivo (zebrafish) | K562 | Vascular regeneration | Wang et al. (2017) |
CPP/CP05 | Exosome/Dystrophin | CD63 | PMO | Conjugated to CP05 via an amide linker | In vivo (Mouse mdx model) | Human serum | Muscle regeneration | Fletcher et al. (2007), Gao et al. (2018) |
CAP | Chondrocytes | lamp2b | miR-140 | Electroporation | In vitro/in vivo (rat osteoarthritis model) | Dendritic cells | Cartilage regeneration | Liang et al. (2020) |
NP41/CP05 | Exosome/Nerve tissue | CD63 | None | None | In vitro | Human serum | Neurogenesis | Whitney et al. (2011), Gao et al. (2018) |
CP05 | Exosome/bone tissue | CD63 | VEGF | Electroporation | In vitro/in vivo (radial defect rat model) | ATDC5 | Bone & Vascular Regeneration | Gao et al. (2018), Zha et al. (2021) |
RGE | Neuropilin-1 | Click chemistry | Cur/SPION | Electroporation | In vitro/In vivo (orthotopic glioma mouse model) | Mouse macrophage cell | Tumor | Jia et al. (2018) |
RVG | Neuronal cells | Lamp2b | BACE1 siRNA | Electroporation | In vivo | Dendritic cells | Neurogenesis | Alvarez-Erviti et al. (2011) |
RVG | Cortical neural progenitors | Lamp2b | miRNA-124 | Electroporation | In vivo | Dendritic cells | Neurogenesis | Alvarez-Erviti et al. (2011) |
Abbreviations: Arg-Gly-Asp; RVG, rabies virus glycoprotein; Ac4ManNAz, tetra acetylated N-azidoacetyl-d-mannosamine; CP05, exosomal capture peptides; PMO, phosphorodiamidate morpholino oligomer; CPP, cell-penetrating peptide; CAP, chondrocyte-affinity peptide; NP41, NTQTLAKAPEHT; RGE, RGERPPR; VEGF, vascular endothelial growth factor; Cur, curcumin; SPION, superparamagnetic iron oxide nanoparticles.